GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Interest Expense

Labiana Health (XMAD:LAB) Interest Expense : €-2.11 Mil (TTM As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Labiana Health's interest expense for the six months ended in Dec. 2022 was € -1.07 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2022 was €-2.11 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Labiana Health's Operating Income for the six months ended in Dec. 2022 was € -2.53 Mil. Labiana Health's Interest Expense for the six months ended in Dec. 2022 was € -1.07 Mil. Labiana Health did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Labiana Health Interest Expense Historical Data

The historical data trend for Labiana Health's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Interest Expense Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Interest Expense
-1.94 -2.13 -2.11

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Interest Expense - - -1.04 -1.07

Labiana Health Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Labiana Health  (XMAD:LAB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Labiana Health's Interest Expense for the six months ended in Dec. 2022 was €-1.07 Mil. Its Operating Income for the six months ended in Dec. 2022 was €-2.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2022 was €18.19 Mil.

Labiana Health's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

Labiana Health did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.